Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Asensus Surgical, Inc.
Asensus Surgical makes robotic surgical systems and instruments that help surgeons perform minimally invasive operations in hospitals.
Asensus Surgical makes robots that help surgeons perform minimally invasive surgery. Its main product is the Senhance Surgical System, a set of robotic arms and instruments that a surgeon controls while operating through tiny cuts in the body instead of large open incisions. Hospitals and surgeons are the customers — they buy or lease the system and then buy the disposable instruments used in each operation.
The pitch is straightforward: smaller cuts usually mean less pain, faster recovery, and shorter hospital stays. Robotic systems also give surgeons steadier, more precise control and a magnified 3D view of the surgical site. Asensus also built software it calls "digital laparoscopy," which adds sensing and data tools on top of the robot to help surgeons measure and improve their movements during an operation. The company has had a rough ride. It was formerly called TransEnterix, and it has burned through cash for years while trying to win over hospitals against much bigger competitors in surgical robotics. It was listed on the NYSE American exchange, but its shares no longer trade, and today the business is in the hands of its owners rather than public stockholders. That is the key thing to know: this is a small, cash-hungry medical device maker that never reached the scale its founders hoped for.
The business is easy to understand in one line: sell expensive robots to hospitals, then earn recurring revenue from the instruments each surgery consumes. The hard part is that hospitals adopt surgical robots slowly, and the market is dominated by larger, better-funded players. Asensus's future depends on whether its installed base of systems grows fast enough to generate the instrument sales that keep the company alive.
Saved answer · last researched 15 Nov 2026